Diagnostic accuracy of bronchoalveolar lavage fluid-based testing for pulmonary cryptococcosis: A systematic review and meta-analysis.

Diagn Microbiol Infect DisAug 10, 2026 (epub)
Clinical ResearchInfectious DiseasesPulmonology

Zongsheng Tian, Xueyan Sun, Zuojuan Zhang et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis evaluated the diagnostic accuracy of bronchoalveolar lavage fluid (BALF)-based testing for pulmonary cryptococcosis. The analysis included various studies and found a pooled sensitivity of 0.87 and specificity of 0.99, indicating high diagnostic accuracy for these tests. The study supports the use of CrAg in BALF as a valuable diagnostic tool.

Key findings

  • Pooled sensitivity of BALF-based testing for pulmonary cryptococcosis was 0.87 (95% CI: 0.81-0.91).
  • Pooled specificity was 0.99 (95% CI: 0.982-0.995).
  • The positive likelihood ratio (PLR) was 88.00 (95% CI: 47.39-163.42).
  • The diagnostic odds ratio (DOR) was 658.50 (95% CI: 285.36-1519.55).

Why it matters

The high sensitivity and specificity of BALF-based testing for pulmonary cryptococcosis highlight its potential as a reliable diagnostic method, especially in cases where invasive procedures are not feasible. This can lead to timely diagnosis and treatment.

Source

PubMed · PMID 42607622

Published in Diagn Microbiol Infect Dis. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Infectious Diseases

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.